Pirtobrutinib,Idelalisib,Bendamustine,Rituximab
Gilead,eli lilly
['bruin cll-321', 'bruin,cll,321', 'bendamustine', 'bruin', 'idelalisib', 'cll', 'ritux', 'rituximab', 'valent ,(-prevalent),(-equivalent),(-bivalent)', 'valent ,(-prevalent)', 'loxo']
#asco23 trial in progress poster: bruin cll-321, a phase 3 open-label, randomized study of a non-covalent (reversible) btki vs. investigator s choice of idelalisib + rituximab or bendamustine + rituximab in btki pretreated cll/sll. view trial info here: 
Dedicated to communicating the latest science & innovation from Loxo@Lilly. Tweets intended for US oncology HCPs. See our community guidelines: https://t.co/1q8vAe63mK